Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2023-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事对相关事项之事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement of prior approval opinions by independent directors regarding the company's reappointment of the audit firm for the 2023 fiscal year and related party transactions for 2022 and 2023. It references regulatory rules for independent directors and audit firm qualifications. The content is focused on governance and compliance matters related to audit and related party transactions, not the audit report itself or the annual report. The document is short (759 characters) and serves as an official opinion or announcement rather than a full audit or financial report. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit-related reports and opinions, excluding full annual reports. FY 2022
2023-03-27 Chinese
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度内部控制自我评价报告" which translates to "2022 Annual Internal Control Self-Evaluation Report". It discusses the company's internal control evaluation for the fiscal year ending December 31, 2022, including the scope, methodology, and conclusions about the effectiveness of internal controls over financial reporting and non-financial reporting. The document is detailed, contains substantive content about internal control evaluation, and is not merely an announcement or certification. It aligns with the characteristics of an Audit Report / Information (AR) as it focuses on internal control evaluation and related audit-like assessments rather than a full annual report or other categories. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-03-27 Chinese
2022年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '安徽安科生物工程(集团)股份有限公司2022 年年度报告摘要' which translates to 'Anhui Anke Biological Engineering (Group) Co., Ltd. 2022 Annual Report Summary'. It contains detailed financial data for the year 2022, including revenue, net profit, earnings per share, and other financial metrics. It also includes comprehensive business descriptions, product lines, R&D activities, patents, shareholder information, and management discussions. The document is about 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content and structure align with an Annual Report, which covers company activity and full financial performance for the fiscal year. Therefore, the document should be classified as an Annual Report (10-K). FY 2022
2023-03-27 Chinese
2022年年度报告及摘要披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is very short (310 characters) and is an announcement stating that the company's 2022 Annual Report and its summary have been disclosed on a regulatory website. It does not contain the actual report or financial data but directs investors to where the report can be found. According to the MENU VS MEAL RULE, this is a Report Publication Announcement (RPA), not the Annual Report (10-K) itself.
2023-03-27 Chinese
关于2022年度日常关联交易确认和2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biological Engineering (Group) Co., Ltd. regarding the confirmation of daily related party transactions for the year 2022 and the forecast for 2023. It includes detailed descriptions of related party transactions, amounts, pricing principles, related parties' background, and independent directors' opinions. The document is a formal announcement about related party transactions, which is a regulatory disclosure but does not contain comprehensive financial statements or detailed financial performance data. It is not an annual report, interim report, earnings release, or any other detailed financial report. It is also not a board or management change announcement, nor a voting result or proxy solicitation. The document is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS). The document length is 6185 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-03-27 Chinese
关于续聘公司2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's decision to reappoint its audit firm for the 2023 fiscal year. It details the audit firm's qualifications, personnel, independence, and audit fees, and mentions that the reappointment will be submitted to the shareholders' meeting for approval. The document does not contain actual financial statements or audit results but is a formal notice about the audit engagement for the upcoming year. The document length is 3287 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, as it relates specifically to audit matters but is not a full annual report or audit opinion report itself. However, given the short length and nature as an announcement of audit firm reappointment, it aligns more closely with Audit Report / Information (AR) rather than a full Annual Report (10-K) or Regulatory Filing (RNS). FY 2023
2023-03-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.